CD8A and metastatic neoplasm: Most of patients with high IF CD3 expression in metastatic tumors [out of 31 (96.7%); IHC score 2+ and 3+] and all patients with and CD8+ and PD‐L1 in metastases (n = 7) had tumors less than 5 cm in diameter and 70% (21 out of 31 patients) and 85%, respectively, had only one metastatic site.